|
Name |
Spiro[benzofuran-2(3H),1'-[2]cyclohexene]-3,4'-dione, 5,7-dichloro-2',4,6-trimethoxy-6'-methyl-, (2S-trans)-
|
Molecular Formula | C17H16Cl2O6 | |
IUPAC Name* |
(2S,5'R)-5,7-dichloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
|
|
SMILES |
C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C(=C3OC)Cl)OC)Cl)OC
|
|
InChI |
InChI=1S/C17H16Cl2O6/c1-7-5-8(20)6-9(22-2)17(7)16(21)10-13(23-3)11(18)15(24-4)12(19)14(10)25-17/h6-7H,5H2,1-4H3/t7-,17+/m1/s1
|
|
InChIKey |
VOYKFNUPFUJNKL-GJEGPGMTSA-N
|
|
Synonyms |
55555-63-0; Spiro[benzofuran-2(3H),1'-[2]cyclohexene]-3,4'-dione, 5,7-dichloro-2',4,6-trimethoxy-6'-methyl-, (2S-trans)-; 5-chlorogriseofulvin; (+)-5-chlorogriseofulvin; DTXSID601109132; (2S)-5,7-Dichloro-2',4,6-trimethoxy-6'beta-methylspiro[benzofuran-2(3H),1'-[2]cyclohexene]-3,4'-dione
|
|
CAS | 55555-63-0 | |
PubChem CID | 10407853 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 387.2 | ALogp: | 2.8 |
HBD: | 0 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 71.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 25 | QED Weighted: | 0.774 |
Caco-2 Permeability: | -4.562 | MDCK Permeability: | 0.00002160 |
Pgp-inhibitor: | 0.583 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.027 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.104 | Plasma Protein Binding (PPB): | 89.75% |
Volume Distribution (VD): | 1.17 | Fu: | 5.17% |
CYP1A2-inhibitor: | 0.245 | CYP1A2-substrate: | 0.982 |
CYP2C19-inhibitor: | 0.501 | CYP2C19-substrate: | 0.896 |
CYP2C9-inhibitor: | 0.72 | CYP2C9-substrate: | 0.083 |
CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.135 |
CYP3A4-inhibitor: | 0.719 | CYP3A4-substrate: | 0.904 |
Clearance (CL): | 8.972 | Half-life (T1/2): | 0.13 |
hERG Blockers: | 0.033 | Human Hepatotoxicity (H-HT): | 0.918 |
Drug-inuced Liver Injury (DILI): | 0.869 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.901 | Maximum Recommended Daily Dose: | 0.513 |
Skin Sensitization: | 0.651 | Carcinogencity: | 0.832 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.14 |
Respiratory Toxicity: | 0.937 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001073 | 0.692 | D0C1SF | 0.692 | ||||
ENC002478 | 0.566 | D02LZB | 0.291 | ||||
ENC002579 | 0.566 | D09DHY | 0.289 | ||||
ENC003538 | 0.512 | D04TDQ | 0.288 | ||||
ENC003637 | 0.457 | D0G4KG | 0.263 | ||||
ENC001494 | 0.435 | D06GCK | 0.248 | ||||
ENC004226 | 0.371 | D01FFA | 0.237 | ||||
ENC003227 | 0.354 | D0D4HN | 0.236 | ||||
ENC003719 | 0.333 | D0L1JW | 0.225 | ||||
ENC005701 | 0.329 | D0Q4YI | 0.222 |